Retrospective Study on Economy and Efficacy of Osimertinib in Posterior-line Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer

HE Tingting; WANG Yubo; FU Ming

doi:10.14009/j.issn.1672-2124.2023.02.002

您当前的位置：

首页 >

文章列表页 >

Retrospective Study on Economy and Efficacy of Osimertinib in Posterior-line Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer

更新时间：2023-04-14

- Retrospective Study on Economy and Efficacy of Osimertinib in Posterior-line Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer
- Issue 2, Pages: 136-138(2023)
- 作者机构：
  
  中国人民解放军陆军特色医学中心呼吸与危重症医学科
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2023.02.002
  CLC： R734.2
- Published：2023，
扫描看全文
HE Tingting, WANG Yubo, FU Ming. Retrospective Study on Economy and Efficacy of Osimertinib in Posterior-line Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer. [J]. (2):136-138(2023)
DOI：

HE Tingting, WANG Yubo, FU Ming. Retrospective Study on Economy and Efficacy of Osimertinib in Posterior-line Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer. [J]. (2):136-138(2023) DOI： 10.14009/j.issn.1672-2124.2023.02.002.

摘要

目的：通过比较奥希替尼与化疗治疗非小细胞肺癌（NSCLC）患者的疗效及日均医疗费用，了解奥希替尼在EGFR T790M阳性NSCLC患者中的应用，为奥希替尼的临床应用提供循证医学证据。方法：回顾性分析2014—2020年该院呼吸与危重症医学科经第1代表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗进展的339例NSCLC患者，根据治疗方案分为奥希替尼组、化疗组和其他治疗组，使用Graphpad和SPSS软件进行疗效和卫生经济学分析。结果：在疗效方面，奥希替尼组患者的无进展生存期明显长于化疗组（11.4个月vs. 4.0个月，P＜0.000 1）

总生存期较化疗组和其他治疗组更长（36.60个月vs. 25.95个月vs. 16.83个月，P＜0.000 1）。日均医疗费用比较，奥希替尼组患者明显低于化疗组（80.86元vs. 150.32元，U=1 947.000

P＜0.000 1）

差异均有统计学意义。结论：对于经第1代EGFR-TKI治疗进展的T790M阳性NSCLC患者，奥希替尼作为后线治疗可能是一种高效、低毒且具有成本效益的选择。

Abstract

OBJECTIVE: To compare the efficacy and average daily medical cost of osimertinib and chemotherapy in posterior-line treatment for patients with non-small cell lung cancer（NSCLC）

and to investigate the application of osimertinib in patients with EGFR T790M-positive NSCLC

so as to provide evidence-based medical evidence for osimertinib. METHODS: Retrospective analysis on 339 patients with NSCLC who progressed through the first generation of EGFR-TKI treatment in the department of respiratory and critical care medicine of this hospital from 2014 to 2020

which were divided into osimertinib group

chemotherapy group and other treatment group according to different treatment regimens

the efficacy and health economics analyses were performed by using Graphpad and SPSS software. RESULTS: In terms of efficacy

patients in the osimertinib group had significantly longer progression-free survival（11.4 months vs. 4.0 months

P<0.000 1） than that in the chemotherapy group and significantly longer overall survival（36.60 months vs. 25.95 months vs. 16.83 months

P<0.000 1） than that in the chemotherapy group and the other treatment groups. Comparing the average daily medical costs

patients in the osimertinib group were significantly lower than that in the chemotherapy group（80.86 yuan vs. 150.32 yuan

U=1 947.000

P<0.000 1）

all differences were statistically significant. CONCLUSIONS: For T790M-positive NSCLC patients who have progressed through the first generation of EGFR-TKI treatment

osimertinib may be an efficient

low-toxic and cost-effective option as a posterior-line treatment.

关键词

奥希替尼EGFR T790M非小细胞肺癌后线治疗

Keywords

OsimertinibEGFR T790MNon-small cell lung cancerPosterior-line treatment

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical Efficacy and Safety of Osimertinib in the Treatment of EGFR Gene Mutation-Positive NSCLC Patients in the Real World

Systematic Review of Huisheng Oral Liquid on Coagulation Function, Efficacy and Safety of Patients with Non-Small Cell Lung Cancer

Prognosis and Safety of Programmed Death 1 Inhibitors in First-Line Treatment of Advanced Non-Small Cell Lung Cancer

Meta-Analysis and Safety Evaluation on Clinical Efficacy of Lorlatinib in the Treatment of Non-Small Cell Lung Cancer

Related Author

TU Wenlian

DONG Lanlan

MIN Qiuxia

CAO Wei

ZHANG Yi

ZHANG Jinhua

TIAN Yuan

YANG Xiaoping

Related Institution

Dept.of Pharmacy, the First People’s Hospital of Yunnan/Kunhua Hospital Affiliated to Kunming University of Science and Technology

College of Pharmacy, Dali University

Dept. of Oncology, Jingmen First People’s Hospital

Traditional Chinese Medicine Phenomics Research Center, Traditional Chinese Medicine Hospital Affiliated to Southwest Medical University

Dept. of Internal Medicine of Traditional Chinese Medicine, Shanghai Seventh People’s Hospital

⁰